Successful glucocorticoid withdrawal in Chinese lupus nephritis patients: A single centre experience
International Immunopharmacology · 2023-12 · 125 · 111156
DOI: 10.1016/j.intimp.2023.111156 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-12. Verfasst von Xiaoyuan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Beijing, China; Key laboratory …. Hauptthemen laut MEDLINE: Lupus Nephritis, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Peking University, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the proportion of patients successfully withdrawn from glucocorticoids (GC) in a longitudinal cohort of patients with lupus nephritis over a period of 20 years, clinical and pathological predictors of patients with GC withdrawal and renal outcomes after GC withdrawal were further explored. METHODS: Patients with successful GC withdrawal were identified for the cohort, and the following data were collected: demographic characteristics, clinical manifestations, pathological findings at disease onset, flares, and renal outcomes subsequent to GC withdrawal. RESULTS: There were 365 patients with lupus nephritis included with a median follow-up of 109.5 (83.5,165.3) months in our cohort. A total of 21 patients (5.8 %) achieved successful GC discontinuation, with a median duration of 7.5 (3,10) years necessary for GC withdrawal. The average duration of GC reduction from 7.5 mg/d to complete withdrawal lasted for approximately 25 months (18,30). Patients in the GC-withdrawal group had a lower prevalence of nephrotic syndrome (NS) at onset (28.5 % vs. 47.3 %, P = 0.035), a higher prevalence of positive anti-double-stranded DNA (anti-dsDNA) antibody (85.7 % vs. 61.6 %, P = 0.028) and more severe endocapillary hypercellularity in the renal histopathology evaluations (3(2.5,3) vs. 3(2,3), P = 0.022). NS at disease onset was an independent risk factor to predict unachievable GC withdrawal (OR 0.296, 95 % CI (0.104,0.842), P = 0.022) by multivariate analysis. With a median follow-up of 34 (20,42) months, none of these patients had flares after GC withdrawal. CONCLUSIONS: The discontinuation of GC therapy in LN patients with complete remission and a stable treatment regimen for at least 5 years was feasible without an increased risk of flares, ESKD or death. Low-dose GC withdrawal necessitates a prolonged duration of time and meticulous monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Beijing, China; Key laboratory of Renal Disease, Ministry of Health of China; Key laboratory of Chron…
- Department of Nephrology, Peking University International Hospital, Beijing 102206, PR China. Electronic address: yufengevert1@sina.com.
Förderung
- Peking University
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences
- Chinese Academy of Meteorological Sciences
Zitieren
APA
Li, X., Tan, Y., Yu, F., & Zhao, M. (2023). Successful glucocorticoid withdrawal in Chinese lupus nephritis patients: A single centre experience. International Immunopharmacology, 125, 111156. https://doi.org/10.1016/j.intimp.2023.111156
Vancouver
Li X, Tan Y, Yu F, Zhao M. Successful glucocorticoid withdrawal in Chinese lupus nephritis patients: A single centre experience. International Immunopharmacology. 2023;125:111156. doi:10.1016/j.intimp.2023.111156
BibTeX
@article{Li2023,
author = {Li, Xiaoyuan and Tan, Ying and Yu, Feng and Zhao, Minghui},
title = {Successful glucocorticoid withdrawal in Chinese lupus nephritis patients: A single centre experience},
journal = {International Immunopharmacology},
year = {2023},
volume = {125},
pages = {111156},
doi = {10.1016/j.intimp.2023.111156}
}
EUVIMED